Related Experiment Video

Updated: Jun 20, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Abatacept in difficult-to-treat juvenile idiopathic arthritis

Jasmin B Kuemmerle-Deschner1, Sm Benseler

  • 1Pediatric Rheumatology Clinics, Dept of Pediatrics, University Hospital Tübingen, Germany;

Biologics : Targets & Therapy
|August 27, 2009
PubMed

Insights

Juvenile idiopathic arthritis (JIA) treatment can involve Abatacept (ABA), a selective co-stimulation modulator. While anti-ABA antibodies can form, they don't seem to impact JIA outcomes, suggesting ABA's potential in difficult cases.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Juvenile idiopathic arthritis (JIA) is a leading cause of childhood rheumatic disease and disability.
  • Immune system dysregulation, particularly involving T-cells, is central to JIA pathogenesis.
  • Disease-modifying antirheumatic drugs (DMARDs) are key for managing JIA.

Purpose of the Study:

  • To evaluate the efficacy and safety of Abatacept (ABA) in treating JIA.
  • To investigate the impact of anti-ABA antibodies on treatment outcomes in JIA patients.

Main Methods:

  • Review of existing data on Abatacept use in various JIA subtypes.
  • Analysis of anti-Abatacept antibody formation and its correlation with clinical outcomes, adverse events, and drug concentrations.

Main Results:

  • Abatacept demonstrates effectiveness across all JIA subtypes, with good safety and tolerability.
  • Anti-ABA antibodies were detected in 67% of seropositive patients but were not linked to disease flares or adverse events.
  • Higher frequency of anti-ABA antibodies correlated with sub-therapeutic ABA serum concentrations.

Conclusions:

  • Abatacept is a viable treatment option for JIA, including difficult-to-treat cases and those refractory to TNF-blockade.
  • The presence of anti-ABA antibodies does not appear to compromise Abatacept's safety or efficacy in JIA.
  • Further research is warranted given the limited but promising data on Abatacept in JIA.

Keywords:
abataceptbiologicsjuvenile idiopathic arthritis (JIA)

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...